EUVIMEDEUVIMED entdecken
Multizentrische StudieVergleichsstudie

Lipiodol Combined with Drug-eluting Beads Versus Drug-eluting Beads Alone for Transarterial Chemoembolization of Hepatocellular carcinoma: A Multicenter Study

Kun Ji, Yang Shi, Zhiying Liang, Cong Zhang, Li Jing, Tiantian Xu, Shoujin Cao, Guanhui Zhou, Yunbo Cao, Jiahua Niu, Jinghua Zhu, Jing Ai und 2 weitere

Academic Radiology · 2024

DOI: 10.1016/j.acra.2024.05.033 ↗

Kurz gefasst

Multizentrische Studie in der Zeitschrift Academic Radiology, 2024. Verfasst von Kun Ji und 13 weiteren Autor:innen. Beteiligte Einrichtung: Hepatobiliary and Pancreatic Interventional Treatment Center, Division of Hepatobiliary and Pancreatic Surgery, the First Affiliated Hospital, Zhejia…. Hauptthemen laut MEDLINE: Carcinoma, Hepatocellular, Chemoembolization, Therapeutic, Liver Neoplasms, Ethiodized Oil. Die Arbeit wurde bisher 6-mal zitiert (Crossref) und nennt 37 Literaturangaben.

AbstractSchlagwörterBibliografische AngabenZitierenVerwandte Studien

Abstract (Originalsprache)

RATIONALE AND OBJECTIVES: This study aimed to propose a novel approach of lipiodol combined with drug-eluting beads transarterial chemoembolization (Lipiodol-DEB TACE) and to compare the safety and efficacy with DEB-TACE alone for patients with unresectable hepatocellular carcinoma (HCC). MATERIALS AND METHODS: From the database of four centers, the records of patients with HCC who received DEB-TACE or Lipiodol-DEB TACE as initial treatment were retrospectively evaluated. The tumor response was measured based on the Modified Response Evaluation Criteria in Solid Tumors. Overall survival (OS), progression-free survival (PFS) and adverse events (AEs) were compared between two groups. RESULTS: A total of 244 patients were included with 160 patients receiving DEB-TACE and 84 patients receiving Lipiodol-DEB TACE. Lipiodol-DEB TACE group had higher objective response rate (86.9 % vs. 76.3 %), higher disease control rate (97.6 % vs. 88.8 %), longer median OS (42.6 vs. 25.8 months) and longer median PFS (34.0 vs. 17.0 months) than DEB-TACE group (P < 0.05). There was no significant difference observed in the incidence of AEs between two groups. Cox analysis identified total bilirubin level, maximum tumor diameter, TACE method and portal vein invasion as independent prognostic factors. CONCLUSION: Lipiodol-DEB TACE was a safe option and associated with improved tumor response and survival outcome compared to DEB-TACE alone for selected patients with HCC.

Schlagwörter

MeSH-Schlagwörter (MEDLINE)

Carcinoma, HepatocellularChemoembolization, TherapeuticLiver NeoplasmsEthiodized OilHumansMaleFemaleMiddle AgedRetrospective StudiesTreatment OutcomeAgedAdultAntineoplastic Agents

Stichwörter der Autor:innen

Drug-eluting beadsHepatocellular carcinomaLipiodolTransarterial chemoembolization

Substanzen

Ethiodized OilAntineoplastic Agents

Autor:innen und Institutionen

  • Hepatobiliary and Pancreatic Interventional Treatment Center, Division of Hepatobiliary and Pancreatic Surgery, the First Affiliated Hospital, Zhejiang University School of Medicine, Hangzhou, Zhejiang Province, China.
  • Center of Interventional Medicine, The Fifth Affiliated Hospital of Sun Yat-sen University, Zhuhai, Guangdong Province, China; Department of Radiology, The First People's Hospital of Kashi Area, Kashi, Xinjiang Uygur Au…
  • Department of Radiology, Sun Yat-sen University Cancer Center, State Key Laboratory of Oncology in South China, Guangdong Key Laboratory of Nasopharyngeal Carcinoma Diagnosis and Therapy, Guangzhou, Guangdong Province,…
  • Department of Radiology, The First People's Hospital of Kashi Area, Kashi, Xinjiang Uygur Autonomous Region, China.
  • Department of Ophthalmology, the First Affiliated Hospital, Zhejiang University School of Medicine, Hangzhou, Zhejiang Province, China.
  • Department of Interventional Radiology, the First Affiliated Hospital of Zhengzhou University, Zhengzhou, Henan Province, China.

Zitieren

APA

Ji, K., Shi, Y., Liang, Z., Zhang, C., Jing, L., Xu, T., Cao, S., Zhou, G., Cao, Y., Niu, J., Zhu, J., Ai, J., Li, Z., & Chen, F. (2024). Lipiodol Combined with Drug-eluting Beads Versus Drug-eluting Beads Alone for Transarterial Chemoembolization of Hepatocellular carcinoma: A Multicenter Study. Academic Radiology. https://doi.org/10.1016/j.acra.2024.05.033

Vancouver

Ji K, Shi Y, Liang Z, Zhang C, Jing L, Xu T, et al. Lipiodol Combined with Drug-eluting Beads Versus Drug-eluting Beads Alone for Transarterial Chemoembolization of Hepatocellular carcinoma: A Multicenter Study. Academic Radiology. 2024. doi:10.1016/j.acra.2024.05.033

BibTeX
@article{Ji2024,
  author = {Ji, Kun and Shi, Yang and Liang, Zhiying and Zhang, Cong and Jing, Li and Xu, Tiantian and Cao, Shoujin and Zhou, Guanhui and Cao, Yunbo and Niu, Jiahua and Zhu, Jinghua and Ai, Jing and Li, Zhen and Chen, Feng},
  title = {Lipiodol Combined with Drug-eluting Beads Versus Drug-eluting Beads Alone for Transarterial Chemoembolization of Hepatocellular carcinoma: A Multicenter Study},
  journal = {Academic Radiology},
  year = {2024},
  doi = {10.1016/j.acra.2024.05.033}
}
Kostenlos starten →